[Object] To provide a novel LXRβ agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis； arteriosclerosis such as those resulting from diabetes； dyslipidemia； hypercholesterolemia； lipid-related diseases； inflammatory diseases that are caused by inflammatory cytokines； skin diseases such as allergic skin diseases； diabetes； or Alzheimer's disease.[Solving Means] A carbinol compound represented by the following general formula (I) or salt thereof, or their solvate.
